[Skip to Content]
[Skip to Content Landing]
March 1976

A Multiple-Dose, Controlled Study of Phenelzine in Depression-Anxiety States

Author Affiliations

From the departments of psychiatry (Drs Ravaris, Nies, and Ives) and pharmacology and medicine (Dr Robinson and Ms Korson) and the Biometry Facility (Dr Lamborn), University of Vermont College of Medicine, Burlington. Dr Nies is now with the Department of Psychiatry, Dartmouth Medical School, Hanover, NH, and Dr Lamborn is now with the Biometry Division, Upjohn Research Laboratories, Kalamazoo, Mich. Dr Robinson is a Burroughs Wellcome Fund Scholar in Clinical Pharmacology.

Arch Gen Psychiatry. 1976;33(3):347-350. doi:10.1001/archpsyc.1976.01770030057008

• In a double-blind, controlled experiment, 62 outpatients with symptoms of depression with anxiety were selected for treatment with phenelzine sulfate, 60 mg daily, phenelzine sulfate, 30 mg daily, or placebo for six weeks. Forty-nine patients (79%) completed the experiment.

Phenelzine sulfate, 60 mg daily, was significantly more effective than placebo in relieving symptoms of both depression and anxiety. Phenelzine sulfate, 30 mg daily, did not differ from the placebo. Only phenelzine sulfate, 60 mg daily, resulted in a median inhibition of platelet monoamine oxidase that exceeded 80%.

The results confirm a previous study that found phenelzine to be effective in the treatment of outpatients with depressive-anxiety states. Drug dosage is an important variable influencing clinical outcome in this patient group.